June 6, 2016
(Managed Care Magazine) – Positive findings from a study of an investigational immunotherapy, Toca 511 and Toca FC (Tocagen, Inc.), have been published in Science Translational Medicine. The study, conducted in patients with recurrent brain cancer, showed extended survival compared with matched patients who received the standard-of-care chemotherapy drug lomustine. The article marked the first peer-reviewed publication describing the study of a retroviral replicating vector administered to humans.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.